M3 WAKE RESEARCH POISED TO EXPAND PHASE I TRIAL SERVICES

Rhea-AI Summary

M3 Wake Research has appointed Lucian Cappoli as the new Head of Early Development and Phase I Operations, effective March 7, 2023. Cappoli, who has extensive experience in Phase I clinical research, aims to enhance the capabilities of their Phase I research sites and expand operations across the network. The Raleigh site, operational since 2012, will serve as a cornerstone for this growth. Cappoli expressed enthusiasm for performing early-phase studies, focusing on safety and efficacy to expedite drug delivery to patients. This move positions M3 Wake Research to capitalize on the expanding clinical trial market.

Positive

• Appointment of Lucian Cappoli as Head of Early Development and Phase I Operations indicates strategic leadership.
• Cappoli's extensive Phase I clinical research experience may lead to enhanced operational efficiencies.
• Plans for expanding Phase I trial capabilities could attract more sponsors and increase revenue potential.

Negative

• None.

New Executive Role Will Lead Growth of Phase I Trial Operations Beyond RTP

RALEIGH, N.C., March 7, 2023 /PRNewswire/ -- M3 Wake Research, a leading fully integrated network of clinical research sites and one of North America's largest providers of Phase I-IV clinical trials, announces the appointment of a new executive role to lead and grow Phase I Operations. Lucian Cappoli will serve as Head of Early Development and Phase I Operations. Since joining M3 Wake Research in 2019, Cappoli has led commercial business contracting for the clinical research network. He brings an extensive background in Phase I clinical research experience, including academic and industry research. As Head of Early Development and Phase I Operations, Cappoli will lead M3 Wake Research's future growth initiatives for early phase research, including enhancing capabilities of the network's Phase 1 research sites, and strategically expanding these early phase capabilities to additional sites in the network.

"I look forward to growing our Phase I trial operations nationwide," said Cappoli. "Our Raleigh unit has been performing phase 1 studies for quite some time. I am excited to build on that knowledge base by performing early phase studies not only in healthy volunteers but in patients who are excited about participating in trials that are personal to their own medical condition."

Phase 1 is the first stage of clinical research testing, to determine if assumptions made in the lab remain consistent when the compound is tested in humans. Early phase studies are mostly completed to confirm safety, proof of concept, and efficacy, and additional data may be collected to help inform later phase trials, to improve efficiencies and potentially get the drug to the patient faster, according to Cappoli, who said he was attracted to the growth potential of this opportunity. He looks forward to applying his experience to growing the early phase operations at Wake Research.

"I have held various operational roles in both industry and academic phase 1 research for the past 20 years. This experience has ideally equipped me to grow phase 1 operations for the Wake Research network. Additionally, I enjoy the optimism and fast pace of a phase 1 trial that are required to make them successful," said Cappoli.

The network's Raleigh site has been performing phase I studies since 2012. The 24-bed Raleigh location is well equipped with dedicated laboratory and pharmacy space, conveniently located near downtown Raleigh, as well as several major universities.

About M3 Inc.:

M3 Inc. operates in the US, Asia, and Europe with over 5.8 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Inc. provides services to healthcare and the life science industry. In addition to clinical research, these services include medical education, ethical drug promotion, market research, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Fort Washington, PA, Raleigh, NC, Oxford, London, Paris, Beijing, and Seoul.

About M3-Wake Research, Inc.:

M3-Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device and pharmaceutical industries. M3-Wake Research's 23 sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications.

M3-Wake Research is known for effectively combining strategic volunteer recruitment, rapid trial start-up and subject enrollment/retention with high quality clinical trial conduct, using standardized operating procedures and centralized marketing and advertising to ensure rapid subject enrollment. M3-Wake Research sites have conducted more than 9,100 research studies for hundreds of pharmaceutical and biotech sponsors and CROs. Wake Research's mission is to bring novel medications, biologics, and devices through clinical research to as many people as possible while providing unparalleled service and exceptional value to clinical trial partners and stakeholders. For more information, visit www.wakeresearch.com.

Contact	Andrea Clement
Phone	678.779.7549
Email	abc@clem.co
Website	www.wakeresearch.com www.wakeclinical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/m3-wake-research-poised-to-expand-phase-i-trial-services-301764613.html

SOURCE M3 Wake Research

FAQ

What does the appointment of Lucian Cappoli mean for M3 Wake Research (MTHRY)?

Lucian Cappoli's appointment serves to enhance M3 Wake Research's leadership in Phase I clinical trials, potentially improving operational efficiencies and growth.

When was Lucian Cappoli appointed at M3 Wake Research?

Lucian Cappoli was appointed as Head of Early Development and Phase I Operations on March 7, 2023.

What are the primary goals of M3 Wake Research's new Phase I Operations strategy?

The primary goals include enhancing capabilities of Phase I research sites and strategically expanding these operations across the network.

What is the significance of Phase I trials in clinical research for M3 Wake Research (MTHRY)?

Phase I trials are crucial for testing the safety and efficacy of new compounds, and successful operations can lead to quicker drug availability.